Plasma fatty acid patterns were assessed by gas liquid chromatography in 73 patients with active inflammatory bowel disease and 107 healthy controls.
Abstract
Plasma fatty acid patterns were assessed by gas liquid chromatography in 73 patients with active inflammatory bowel disease and 107 healthy controls. The influence of the disease activity on fatty acid profile was also investigated. Plasma fatty acid patterns in patients with ulcerative colitis and Crohn's disease were similar. Plasma C18:3n3 and C22:6n3 were significantly higher in active ulcerative colitis (p=0.0143 and p<0O00001 respectively) and in Crohn's disease (p<0.00001 for both) than in controls, whereas C20:3n6 was significantly lower in patients than in controls, both in ulcerative colitis (p=0.0001) and in Crohn's disease (p=0.0041). In more severe disease, plasma polyunsaturated fatty acid concentrations fell with a significant stepwise decrease in the desaturation index (p=0.0031 in ulcerative colitis and p=0.0355 in Crohn's disease). Even in patients with severe disease, however, plasma n3 fatty acids (C18:3n3 and C22:6n3) never fell below those of healthy controls. These findings suggest that in active inflammatory bowel disease, an increased biosynthesis might coexist with an increased consumption ofpolyunsaturated fatty acids. These observations may be of relevance in the pathogenesis of the disease as polyunsaturated fatty acids are involved in tissue eicosanoid synthesis and cellular membrane function, including that of immunocompetent cells. These results also question the rationale of using n3 polyunsaturated fatty acids in the treatment of inflammatory bowel disease. (Gut 1992; 33: 1365 -1369 Polyunsaturated fatty acids have essential biological functions. As part of the structure of cell membrane, they exert control on its intrinsic proteins -for example, enzymes, receptors -by inducing changes in membrane fluidity.'2 In addition, the long chain polyunsaturated fatty acids, dihomo-T-linolenic (C20:3n6),3 arachidonic (C20:4n6),5 and eicosapentaenoic (C20: 5n3)6 acids are the precursors of eicosanoids.
Some of the arachidonic acid derived eicosanoids (prostaglandin E2, leukotriene B4, and thromboxane A2) have been incriminated in the pathogenesis of inflammatory bowel disease, because their concentrations increase in the inflamed intestinal mucosa in the acute phase of the disease. There are four different polyunsaturated fatty acid series which share the same desaturases and elongases for their synthesis.'3 '4 Their affinity for these enzymatic systems are different, however. In addition, the components of the different fatty acid series are not interconvertible in vivo.'3 These properties have allowed modification of the eicosanoid synthesis by producing changes in dietary polyunsaturated fatty acids. 5`6 Dietary supplementation with eicosapentaenoic and docosahexaenoic acids rich fish oil induces the appearance of triene prostaglandins and thromboxanes'78 and pentaene leukotrienes'9 with attenuated inflammatory effects.'7 '9 The therapeutic efficiency of eicosapentaenoic acid (C20:5n3) as an antiinflammatory agent in experimental models of inflammation20 21 
Results
The clinical features of the 73 patients included in the study are detailed in Table I . Ulcerative colitis involved the entire colon in 21 patients, the left colon in 12, and was confined to the rectum in eight. Crohn's disease was ileocolic in 10 cases, involved only the small bowel in nine patients, and 13 patients had colonic disease. Tables II and III. ULCERATIVE COLITIS (Table II) The (Table IV) and Crohn's disease patients (Table V) . The plasma values of stearic acid (C18:0) and long chain n3 and n6 polyunsaturated fatty acids decreased stepwise as the disease became more severe. This only reached statistical significance for stearic acid (C18:0) and long chain n6 polyunsaturated fatty acids in ulcerative colitis and for arachidonic acid (C20:4n6) in Crohn's disease.
The decrease in plasma long chain polyunsaturated fatty acids associated to the increase of disease activity, was more marked in the n6 series (arachidonic and dihomo-T-linolenic acid), especially in ulcerative colitis. It is remarkable that, in spite of the progressive fall in plasma docosahexaenoic acid values as inflammatory bowel disease became more severe, its mean value always remained above the mean value of this n3 polyunsaturated fatty acid in healthy individuals. It is also noteworthy that in mild disease, concentrations of long n6 polyunsaturated fatty acids, especially arachidonic acid, also remained above those in healthy controls. The decrease in plasma long chain and highly unsaturated fatty acids in those patients with more severe disease, which resulted in a significant reduction of the unsaturation index, was partly counterbalanced by a significant increase in the percentage of oleic acid (C 18: 1).
Discussion
The most striking result of this study is the increased plasma concentrations of the precursor (ct-linolenic acid) and the end product (docosahexaenoic acid) of the n3 polyunsaturated fatty acid series in active ulcerative colitis and Crohn's disease. In addition, low concentrations of dihomo-t-linolenic (C20:3n6) acid were also found. When patients were grouped according to the severity of the attack, however, a stepwise fall in polyunsaturated fatty acids was observed as the disease became more severe. This was especially marked for long chain n6 polyunsaturated fatty acids in ulcerative colitis and Crohn's disease. It 
